Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Capital Expenditures (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Capital Expenditures for 4 consecutive years, with -$58000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Capital Expenditures fell 105.58% to -$58000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $2.0 million, a 42.13% decrease, with the full-year FY2024 number at $2.3 million, up 123.3% from a year prior.
  • Capital Expenditures was -$58000.0 for Q4 2024 at Lyra Therapeutics, down from $2.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $2.3 million in Q3 2024 to a low of -$797000.0 in Q2 2021.
  • A 4-year average of $433375.0 and a median of $69000.0 in 2022 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 5169.57% in 2024; the steepest drop was 3277.78% in 2024.
  • Lyra Therapeutics' Capital Expenditures stood at $1.1 million in 2021, then crashed by 97.41% to $28000.0 in 2022, then skyrocketed by 3610.71% to $1.0 million in 2023, then crashed by 105.58% to -$58000.0 in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Capital Expenditures are -$58000.0 (Q4 2024), $2.3 million (Q3 2024), and -$286000.0 (Q2 2024).